Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

• Published in: The Lancet Oncology
• Main Authors: McPhail, Sean, Barclay, Matthew E., Swann, Ruth, Johnson, Shane A., Alvi, Riaz, Barisic, Andriana, Bucher, Oliver, Creighton, Nicola, Denny, C.A., Dewar, R.A., Donnelly, D.W., Dowden, Jeff J., Downie, Laura, Finn, Nora, Gavin, Anna T., Habbous, Steven, Huws, Dyfed W., Kumar, S. Eshwar, May, Leon, McClure, Carol A., Morrison, David S., Møller, Bjorn, Musto, Grace, Nilssen, Yngvar, Saint-Jacques, Nathalie, Sarker, Sabuj, Shack, Lorraine, Tian, Xiaoyi, Thomas, Robert J. S., Wang, Haiyan, Woods, Ryan R., You, Hui, Zhang, Bin, Lyratzopoulos, Georgios, Bennett, D., Butler, J., Cameron, D.A., Chew, C., Crosby, T., Filsinger, B., Finley, C.J., Forster, K., Fung, S., Green, B., Gomez-Navas, E., Gutierrez, E., Han, J., Harrison, S., Lawler, M., Little, A.L., Pantarotto, J.R., Peacock, S.J., Ray-Coquard, I., Thomson, C.S., Warlow, J.L., Whitfield, E.
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2024
• Subjects: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being; Newfoundland; Norway; Prince Edward Island
• Online Access: https://pure.qub.ac.uk/en/publications/2b75e872-c10c-4d45-99d7-c9611e42799d; https://doi.org/10.1016/S1470-2045(24)00032-9; https://pureadmin.qub.ac.uk/ws/files/595750817/StudyShip.pdf

Background There is little evidence on variation in radiotherapy use in different countries, although it is a key treatment modality for some patients with cancer. Here we aimed to examine such variation. Methods This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), nine Canadian provinces (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria). Patients aged 15–99 years diagnosed with cancer in eight different sites (oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer), with no other primary cancer diagnosis occurring within the 5 years before to 1 year after the index cancer diagnosis or during the study period were included in the study. We examined variation in radiotherapy use from 31 days before to 365 days after diagnosis and time to its initiation, alongside related variation in patient group differences. Information was obtained from cancer registry records linked to clinical or patient management system data, or hospital administration data. Random-effects metaanalyses quantified interjurisdictional variation using 95% prediction intervals (95% PIs). Findings Between Jan 1, 2012, and Dec 31, 2017, of 902 312 patients with a new diagnosis of one of the studied cancers, 115 357 (12·8%) did not meet inclusion criteria, and 786,955 were included in the analysis. There was large interjurisdictional variation in radiotherapy use, with wide 95% PIs: 17·8 to 82·4 (pooled estimate 50·2%) for oesophageal cancer, 35·5 to 55·2 (45·2%) for rectal cancer, 28·6 to 54·0 (40·6%) for lung cancer, and 4·6 to 53·6 (19·0%) for stomach cancer. For patients with stage 2–3 rectal cancer, interjurisdictional variation was greater than that for all patients with rectal cancer (95% PI 37·0 to 84·6; pooled estimate 64·2%). Radiotherapy use was infrequent but variable in patients with pancreatic ...